Recurrent infection with human respiratory syncytial virus (RSV) is one of the most common causes for lower respiratory tract illness (LRI) in infants, the elderly, and immunocompromised individuals. Due to lack of vaccines and therapeutic interventions, medical care of acute RSV bronchiolitis is mostly limited to supportive measures. Thus, novel treatment options to control RSV infection are desperately required. The cationic host defence peptide human cathelicidin LL-37 possesses both microbicidal and immunomodulatory properties. This essential effector of the innate immune system holds potent antiviral activity against a variety of viruses, including influenza virus, and has been proposed as a promising candidate for antiviral drug development. Previous studies revealed that lower cathelicidin levels put RSV infected infants at risk for more severe RSV disease, while infection of lung epithelial cells induced cathelicidin up-regulation. These findings suggest that LL-37 might possess antiviral activity against RSV. However, its potential antiviral function on RSV remains to be elucidated. This thesis therefore aimed to evaluate the antiviral activity of cathelicidins against RSV, by assessing its relevance in vitro and in vivo and elucidating the underlying antiviral mechanism. Firstly, the antiviral effects of human cathelicidin LL-37 against RSV were addressed in vitro. Presence of LL-37 during infection potently reduced viral titres and protected cells against virus-associated cytopathic effects. Experiments revealed that only the core region of LL-37 holds antiviral activity against RSV. Antiviral effects were also observed for the murine LL-37 orthologue mCRAMP. Administration of LL-37 at different stages in the infection cycle provided evidence that LL-37 can be used preventatively, protecting against RSV infection by directly acting on both cells and viral particles. When given therapeutically, once an infection was established, LL-37 also limited viral spread. Next, the molecular mechanism mediating the peptide’s antiviral activity was investigated. It was demonstrated that LL-37 does not affect the interferon-mediated cellular antiviral immune response to RSV. Experiments established that LL-37 does not contribute to viral clearance by inducing epithelial cell death. Further mechanistic studies revealed that the peptide directly binds to RSV particles, destabilises the integrity of the viral envelope, and prevents adsorption of RSV to epithelial cells during the entry stage of infection. Finally, the in vivo relevance of LL-37 treatment and endogenous cathelicidin expression was examined, employing both murine and human model systems. It was established that LL-37 has protective antiviral effects against RSV in vivo. In contrast to the cell culture model, only co-administration of LL-37 and RSV, but not treatment prior or post infection, protects mice from clinical signs of infection. Levels of the murine LL-37 orthologue mCRAMP were increased in RSV infected lungs, pointing towards its importance in antiviral defence. In keeping with this, mCRAMP-deficient mice were more susceptible to RSV induced disease. Equally, individuals with low nasal LL-37 baseline levels that were experimentally challenged with RSV, were more susceptible to infection. This highlights the importance of endogenous cathelicidin expression to fight and control RSV infection. Overall, these results identify LL-37 as an important antiviral agent against RSV in vitro and in vivo, and emphasise the role of endogenous cathelicidins in the defence against this pathogen. Moreover, unravelling the underlying antiviral mechanism of LL-37 against RSV adds to our understanding of how CHDP act on enveloped viruses, thus supporting the development of new antiviral treatment options.

Respiratory syncytial virus (RSV) is the primary viral pathogen responsible for lower respiratory tract disease in neonates and young children worldwide. By the age of two, virtually all children have been infected with RSV, and approximately 40% of them develop lower respiratory tract infections. In addition to acute morbidity, an association between RSV infection in early childhood and later development of recurrent wheezing and airway hyperresponsiveness (AHR) has been repeatedly demonstrated.<p>In this work we established a method for propagating pneumonia virus of mice (PVM) in a baby hamster kidney-21 (BHK-21) cell line. We also modified the standard plaque assay method and established a reliable and, most importantly, reproducible way to quantitate PVM. In our work we used PVM strain 15 to successfully establish an in vivo animal model for RSV disease in Balb/c and C57/Bl mice. Different susceptibility/resistance patterns to a pathogen exist for different mouse strains. In the case of Balb/c and C57/Bl mice, these patterns are well characterized for several pathogens including Leishmania major and adenovirus type 1. Our comparative study demonstrated clear differences in susceptibility to PVM strain 15 infection between Balb/c and C57/Bl mice; Balb/c mice being more susceptible.<p> In peripheral sites, dendritic cells (DCs) serve as sentinel cells that take up and process antigens. Numerous studies revealed that certain pathogens stimulate changes in DC phenotypic characteristics and thus contribute to functional alterations that lead to inappropriate T cell activation and disease augmentation. To examine effects of PVM on DCs, we infected bone marrow dendritic cells (BM-DCs) derived from both mouse strains with PVM, and evaluated their phenotypic and functional characteristics 24 hours post infection. Under these experimental conditions, PVM infected BM-DCs did not show a significant increase in the expression of costimulatory and major histocompatibility complex class II (MHC II) molecules compared to uninfected controls. Furthermore, there were no changes in the ability of PVM-infected DCs to take up soluble antigen. The production of IL-12p70, the pivotal cytokine in the development of a Th1-type response, by the PVM-infected BM-DCs was not significantly different from uninfected cells. In addition, there was no significant impact of PVM infection on the ability of DCs to induce naïve T cell proliferation.

Respiratory syncytial virus (RSV) is the primary viral pathogen responsible for lower respiratory tract disease in neonates and young children worldwide. By the age of two, virtually all children have been infected with RSV, and approximately 40% of them develop lower respiratory tract infections. In addition to acute morbidity, an association between RSV infection in early childhood and later development of recurrent wheezing and airway hyperresponsiveness (AHR) has been repeatedly demonstrated.<p>In this work we established a method for propagating pneumonia virus of mice (PVM) in a baby hamster kidney-21 (BHK-21) cell line. We also modified the standard plaque assay method and established a reliable and, most importantly, reproducible way to quantitate PVM. In our work we used PVM strain 15 to successfully establish an in vivo animal model for RSV disease in Balb/c and C57/Bl mice. Different susceptibility/resistance patterns to a pathogen exist for different mouse strains. In the case of Balb/c and C57/Bl mice, these patterns are well characterized for several pathogens including Leishmania major and adenovirus type 1. Our comparative study demonstrated clear differences in susceptibility to PVM strain 15 infection between Balb/c and C57/Bl mice; Balb/c mice being more susceptible.<p> In peripheral sites, dendritic cells (DCs) serve as sentinel cells that take up and process antigens. Numerous studies revealed that certain pathogens stimulate changes in DC phenotypic characteristics and thus contribute to functional alterations that lead to inappropriate T cell activation and disease augmentation. To examine effects of PVM on DCs, we infected bone marrow dendritic cells (BM-DCs) derived from both mouse strains with PVM, and evaluated their phenotypic and functional characteristics 24 hours post infection. Under these experimental conditions, PVM infected BM-DCs did not show a significant increase in the expression of costimulatory and major histocompatibility complex class II (MHC II) molecules compared to uninfected controls. Furthermore, there were no changes in the ability of PVM-infected DCs to take up soluble antigen. The production of IL-12p70, the pivotal cytokine in the development of a Th1-type response, by the PVM-infected BM-DCs was not significantly different from uninfected cells. In addition, there was no significant impact of PVM infection on the ability of DCs to induce naïve T cell proliferation.

No description available.

Made available in DSpace on 2015-09-17T15:24:06Z (GMT). No. of bitstreams: 0 Previous issue date: 2013-05-24. Added 1 bitstream(s) on 2015-09-17T15:48:25Z : No. of bitstreams: 1 000846074.pdf: 3890314 bytes, checksum: df88ab7c4eb07c7c4d59dc314f2c9515 (MD5) / O Vírus Sincicial Respiratório Humano (hRSV) é o maior causador de infecções respiratórias agudas (IRAs) em recém-nascidos e crianças no mundo inteiro. Seu genoma codifica 11 proteínas entre as quais as proteínas de superfície F, G e SH que são responsáveis pela entrada e instalação do vírus na célula do hospedeiro. Entre as proteínas de superfície, pouco se sabe sobre a função da proteína SH. O objetivo do presente estudo foi realizar a modelagem e caracterização da proteína SH e análizar o seu comportamento estrutural em diferentes meios: água e bicamada fosfolipídica. O modelo da proteína SH foi gerado pelo servidor I-Tasser, e suas características funcionais e estruturais analisados pelo PredictProtein e PsiPred. Simulações de Dinâmica Molecular foram realizadas para análise da hidrofobicidade da região central da proteína, do seu comportamento em membrana lipídica e possível formação de oligômeros. Os resultados da predição do modelo da proteína SH resultou em uma estrutura linear com uma alfa-hélice compreendida entre os aminoácido 20-42 e as análises realizadas pelo PsiPred indicaram essa região como sendo uma região transmembrânica. As simulações de Dinâmica Molecular mostraram que, quando em solução, a proteína muda sua conformação linear para globular confirmando a hidrofobicidade do domínio central. A presença da proteína SH sozinha ou das cinco estruturas na bicamada resultou num decréscimo considerável da área por lipídeo, conferindo as cadeias menor mobilidade e um maior alinhamento. As simulações do pentâmero mostraram a passagem de moléculas de água pelo poro em ambiente onde os resíduos de histidinas H22 e H51 apresentaram-se na forma protonada, indicando a dependência desta atividade com o pH do meio. Com base nessas análises foi possível propor uma estrutura terciária e quaternária da proteína SH e, com as análises da formação pentamérica da... / The human Respiratory Syncytial Virus (hRSV) is the major cause of lower respiratory tract illnesses in children and elderly people worldwide. Its genome encodes 11 proteins including the surface protein F, G and SH which are responsible for entry and distribution of virus in the host cell. Among the protein surface, little is known about the function of protein SH. Knowing their structure and function is fundamental to a better understanding of its mechanism. The aim of this study was modeling and caracterization of the RSV SH protein and analysis of structural behavior in different environment : water and phopholipid bilayer for understanding and evaluating the formation of its pentameric structure. The SH protein model was generated by I-TASSER server, and its funcional and structural caracterisct was analyzed by PredictProtein and PsiPred. Molecular Dynimics Simulation were performed for analysis of hidrophobicit of protein central region, studies of the protein behavior on the membrane and pentamer formation. The SH protein model prediction resulted in a linear model with a helix-alpha between amino acid 20-42 and the anlysis performed by PsiPred indicated this region as transmembrane region. Molecular Dynamics Simulation showed that, when in solution,the proteína changes its linear conformations for globular conformation confirming the hydrophobicity of the central domain. The presence of the Sh protein itself or of the pentamer in bilayer resulted in a considerable decrease of the area per lipid, giving the chains less mobility and greater alignment. The pentamer simulation showed passage of water molecules through the pore in an environment where histidine residues H22 and H51 are protonated, indicating the dependence of this activity with the pH of the medium. Based on this analysis, it was proposed the structure tertiary and quaternary of the SH protein and, with the analysis of the ...

No description available.

Background: Respiratory syncytial virus (RSV) is one of the leading causes of acute lower respiratory tract infection and childhood hospitalization worldwide. However, there are currently no vaccines or antivirals available to prevent or treat RSV infections. Of the 11 proteins encoded by RSV’s negative-sense single-stranded RNA genome, the nucleoprotein, phosphoprotein, and large polymerase interact through well characterized domains to form the RNA-dependent RNA polymerase complex. This polymerase complex is essential for viral replication and virulence, which makes it an excellent antiviral target. Previous studies have shown that the nucleoprotein-phosphoprotein interaction of the polymerase complex can be disrupted by synthetic peptides of the last 21 C-terminal (P220-241) or the first 29 N-terminal (P1-29) amino acids of the phosphoprotein. Objective: The Mahony lab has also previously demonstrated that P220-241 conjugated to a maltose binding protein (MBP) and HIV-1 Tat cell penetrating peptide (CPP) could inhibit up to 90% of RSV A replication in vitro. However, the bacterial derived MBP is immunogenic. This study builds on these findings by developing and evaluating the efficacy of a P220-241 peptide mimetic conjugated to human thioredoxin (hTrx) carrier protein and a P1-29 peptide mimetic conjugated to MBP. Methods and Results: Inverse PCR and In-Fusion® cloning was used to clone a hTrx-P220-241 plasmid, which was then expressed as a recombinant protein and purified by affinity chromatography for functional analysis. HTrx-P220-241 was shown to specifically interact with RSV nucleoprotein in a glutathione S-transferase (GST) pull down assays and it could successfully enter into LLC-MK2 cells. However, upon challenge with RSV A, LLC-MK2 cells that were incubated with increasing concentrations of hTrx-P220-241 did not inhibit RSV A replication when assessed by indirect immunofluorescence microscopy. The MBP-P1-29 construct did not exhibit any significant cytotoxicity in LLC-MK2 cells nor BEAS-2B cells. Upon challenge with RSV A, LLC-MK2 cells and BEAS-2B cells pre-treated with MBP-P1-29 demonstrated a dose-dependent inhibition of RSV replication in vitro, with a percent inhibition of infection of 80% and 60% respectively. Furthermore, MBP-P1-29 also reduced the release of infectious progeny virion by up to 74% in LLC-MK2 cells and 34% in BEAS-2B cells. Conclusion: Phosphoprotein peptide mimetics targeting essential nucleoprotein-phosphoprotein interaction are a promising approach in the development of therapeutic treatments for RSV. In this study, a P220-241 peptide mimetic conjugated to a human thioredoxin scaffold protein was not able to inhibit RSV A replication while a P1-29 peptide attached to a maltose binding protein was effective in reducing RSV replication in vitro. Thus, further studies are required to evaluate a P1-29 peptide mimetic against different RSV A and B strains and to find an appropriate human carrier protein to attach it to. / Thesis / Master of Science (MSc) / Respiratory syncytial virus is a respiratory illness that is one of the leading causes of childhood hospitalization worldwide. RSV infects almost all infants at least once by the age of two. It can also repeatedly infect individuals throughout their lives, which puts the elderly and individuals with weak immune, cardiac or pulmonary systems at risk. There are also no approved vaccines or antiviral treatments available to prevent or combat a RSV infection, which highlights the pressing need for the development of new antiviral drugs. This thesis focuses on developing and evaluating the efficacy of two different antiviral peptides, which both target and disrupt the formation of the viral machinery required for the replication of the RSV genome.

Respiratory syncytial virus (RSV) is the leading cause of respiratory illness in children worldwide. RSV has a negative sense RNA genome, which is the template for viral mRNA transcription and genome replication, and encodes a polymerase to carry out viral RNA synthesis. The promoters for RSV transcription and genome replication are found in a 44-nucleotide (nt), 3´-extragenic region called the leader (Le). Replication is initiated opposite the first nt of the Le, and transcription of the first gene begins at position +45, at a gene start (GS) sequence. However, transcription is also dependent on sequence within Le1-12. Interestingly, Le nucleotides 3-12 bear strong similarity to a GS signal. We hypothesized that this GS-like sequence is the recruitment site for transcribing polymerase. To test this hypothesis, we examined RNA synthesis events at the Le promoter. We identified a previously undescribed RNA initiation site at Le position +3 (Le+3) that was used frequently during RSV infection. Initiation at Le+3 led to the production of a small ~25 nt RNA. Le+3 initiation was shown to occur independently of replication initiation at +1, indicating it is a bona fide initiation site. Mutation of Le1-12 to increase similarity to a GS resulted in elongation of Le+3 RNA and a decrease in transcription initiation at the GS, demonstrating that the Le initiation sequence alters polymerase processivity and impacts downstream transcription events. Preliminary experiments to determine the function of the small RNA showed that it increased levels of viral RNA replication, suggesting it may be involved in influencing a switch from transcription to replication. These studies suggest a model for RSV transcription initiation, whereby the transcribing polymerase enters at the 3´&ndash;end of the genome, initiates RNA synthesis from Le+3 and generates a small RNA, and is then positioned to initiate transcription at the first GS. The small RNA that is generated may act as a feedback molecule to promote RNA replication. These findings provide a greater understanding of polymerase behavior at the promoter and may inform rational drug and vaccine design.

No description available.

No description available.